File Download
  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Over-expressions of AMPK subunits in ovarian carcinomas with significant clinical implications

TitleOver-expressions of AMPK subunits in ovarian carcinomas with significant clinical implications
Authors
Issue Date2012
PublisherBioMed Central Ltd. The Journal's web site is located at http://www.biomedcentral.com/bmccancer/
Citation
BMC Cancer, 2012, v. 12, article no. 357 How to Cite?
AbstractABSTRACT: BACKGROUND: AMP-activated protein kinase (AMPK) has recently been considered as a potential target for cancer therapy. However, the expression status of various subunits of the heterotrimeric AMPK in human cancers is rarely reported. We decided to determine their expressions in ovarian carcinomas and their relationships with the disease. METHODS: Expressions and locations of the AMPK-alpha1, -alpha2, -beta1, -beta2, -gamma1 and -gamma2 were detected by quantitative PCR (Q-PCR) and immunohistochemical staining (IHC). Their expression levels in ovarian tumors were compared with normal controls and also correlated with clinicopathological parameters. RESULTS: Except AMPK-alpha1, expressions of the other five AMPK subunits are significantly higher in ovarian carcinomas as determined by Q-PCR. Although IHC detection of AMPK-gamma1 and -gamma2 were not successful, over-expressions of AMPK-alpha2, -beta1, and -beta2 were further confirmed by IHC. Over-expressions of various AMPK subunits occurred independently and were mainly detected in the cytoplasm. Interestingly, AMPK-alpha2 and -beta1 were also detected in the nucleus and cell membrane, respectively. Clinical correlation analyses indicate that expressions of different AMPK subunits are associated with different subtypes of carcinoma. High expression of AMPK-alpha2 is significantly associated with endometrioid carcinomas. On the other hand, high expressions of AMPK-beta and -gamma subunits are associated with mucinous and serous carcinomas, respectively. Furthermore, high expressions of AMPK-beta1 and -gamma2 are also associated with early and late stages of disease, respectively. Finally, patients with high expression of AMPK-alpha2 had better prognosis. CONCLUSIONS: Aberrant expressions of AMPK subunits may play important roles in ovarian carcinogenesis. Each AMPK subunit may have its own function other than just a component of the AMPK molecule. Correlations with clinical parameters suggest that expressions of AMPK subunits have different clinical implications in ovarian cancer development.
Persistent Identifierhttp://hdl.handle.net/10722/164814
ISSN
2014 Impact Factor: 3.362
2013 SCImago Journal Rankings: 1.686
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorLi, Cen_US
dc.contributor.authorLiu, VWSen_US
dc.contributor.authorChiu, PMen_US
dc.contributor.authorChan, DWen_US
dc.contributor.authorNgan, HYSen_US
dc.date.accessioned2012-09-20T08:10:05Z-
dc.date.available2012-09-20T08:10:05Z-
dc.date.issued2012en_US
dc.identifier.citationBMC Cancer, 2012, v. 12, article no. 357en_US
dc.identifier.issn1471-2407-
dc.identifier.urihttp://hdl.handle.net/10722/164814-
dc.description.abstractABSTRACT: BACKGROUND: AMP-activated protein kinase (AMPK) has recently been considered as a potential target for cancer therapy. However, the expression status of various subunits of the heterotrimeric AMPK in human cancers is rarely reported. We decided to determine their expressions in ovarian carcinomas and their relationships with the disease. METHODS: Expressions and locations of the AMPK-alpha1, -alpha2, -beta1, -beta2, -gamma1 and -gamma2 were detected by quantitative PCR (Q-PCR) and immunohistochemical staining (IHC). Their expression levels in ovarian tumors were compared with normal controls and also correlated with clinicopathological parameters. RESULTS: Except AMPK-alpha1, expressions of the other five AMPK subunits are significantly higher in ovarian carcinomas as determined by Q-PCR. Although IHC detection of AMPK-gamma1 and -gamma2 were not successful, over-expressions of AMPK-alpha2, -beta1, and -beta2 were further confirmed by IHC. Over-expressions of various AMPK subunits occurred independently and were mainly detected in the cytoplasm. Interestingly, AMPK-alpha2 and -beta1 were also detected in the nucleus and cell membrane, respectively. Clinical correlation analyses indicate that expressions of different AMPK subunits are associated with different subtypes of carcinoma. High expression of AMPK-alpha2 is significantly associated with endometrioid carcinomas. On the other hand, high expressions of AMPK-beta and -gamma subunits are associated with mucinous and serous carcinomas, respectively. Furthermore, high expressions of AMPK-beta1 and -gamma2 are also associated with early and late stages of disease, respectively. Finally, patients with high expression of AMPK-alpha2 had better prognosis. CONCLUSIONS: Aberrant expressions of AMPK subunits may play important roles in ovarian carcinogenesis. Each AMPK subunit may have its own function other than just a component of the AMPK molecule. Correlations with clinical parameters suggest that expressions of AMPK subunits have different clinical implications in ovarian cancer development.-
dc.languageengen_US
dc.publisherBioMed Central Ltd. The Journal's web site is located at http://www.biomedcentral.com/bmccancer/en_US
dc.relation.ispartofBMC Canceren_US
dc.rightsCreative Commons: Attribution 3.0 Hong Kong Licenseen_US
dc.titleOver-expressions of AMPK subunits in ovarian carcinomas with significant clinical implicationsen_US
dc.typeArticleen_US
dc.identifier.emailLi, C: cuilan_li@yahoo.com.cnen_US
dc.identifier.emailLiu, VWS: vwsliu@hku.hken_US
dc.identifier.emailChiu, PM: mchiu@hku.hken_US
dc.identifier.emailChan, DW: dwchan@hku.hken_US
dc.identifier.emailNgan, HYS: hysngan@hkucc.hku.hk-
dc.identifier.authorityLiu, VWS=rp00341en_US
dc.identifier.authorityChan, DW=rp00543en_US
dc.identifier.authorityNgan, HYS=rp00346en_US
dc.description.naturepublished_or_final_version-
dc.identifier.doi10.1186/1471-2407-12-357-
dc.identifier.pmid22897928-
dc.identifier.scopuseid_2-s2.0-84864942652-
dc.identifier.hkuros207469en_US
dc.identifier.volume12, article no. 357en_US
dc.identifier.isiWOS:000312097300001-
dc.publisher.placeUnited Kingdom-
dc.identifier.citeulike11104964-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats